GBIO - Generation Bio Co.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.19
-0.56 (-2.84%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close19.75
Open19.78
Bid19.36 x 800
Ask19.99 x 900
Day's Range19.07 - 19.99
52 Week Range18.51 - 24.90
Volume208,062
Avg. Volume568,141
Market Cap856.534M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Generation Bio Announces Closing of Initial Public Offering

    Generation Bio Co. (GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its initial public offering of 12,105,263 shares of its common stock at an initial public offering price of $19.00 per share, including 1,578,947 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Generation Bio. The shares began trading on the Nasdaq Global Select Market on Friday, June 12, 2020 under the ticker symbol “GBIO.”

  • MarketWatch

    Generation Bio shares soar 23% in trading debut

    Shares of Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, soared 23% Friday in their trading debut, after the IPO was upsized and priced at $19 a share, the high end of its price range. The company sold 10.5 million shares to raise $199.5 million. The shares are trading on Nasdaq, under the ticker symbol "GBIO." J.P. Morgan, Jefferies, Cowen and Wedbush PacGrow were underwriters on the deal. Proceeds will be used to fund R&D, to develop platform technologies and for general corporate purposes. "We are an innovative genetic medicines company creating a new class of gene therapy utilizing our proprietary non-viral gene therapy platform to provide durable, redosable treatments for millions of patients living with rare and prevalent diseases," the company says in its prospectus.

  • MarketWatch

    Generation Bio prices upsized IPO at $19 a share to raise $199.5 million

    Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, priced its upsized initial public offering at $19 a share, the high end of its price range. The company sold 10.5 million shares to raise $199.5 million. The shares will starting trading on Nasdaq later Friday, under the ticker symbol "GBIO." J.P. Morgan, Jefferies, Cowen and Wedbush PacGrow were underwriters on the deal. Proceeds will be used to fund R&D, to develop platform technologies and for general corporate purposes. "We are an innovative genetic medicines company creating a new class of gene therapy utilizing our proprietary non-viral gene therapy platform to provide durable, redosable treatments for millions of patients living with rare and prevalent diseases," the company says in its prospectus.

  • GlobeNewswire

    Generation Bio Announces Pricing of Initial Public Offering

    CAMBRIDGE, Mass., June 11, 2020 -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing.